RxDoctor Payments Data

Dellinia Burgess

Family · Buford, GANPI 1851826390

Payments from drug & device makers

$2,438in general payments, 2019–2025

Across 131 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$605
  • Lilly USA, LLC$345
  • AbbVie$296
  • Inspire Medical Systems, Inc.$108
  • Amarin Pharma, Inc.$103
  • Takeda Pharmaceuticals U.S.A., Inc.$87
  • plus $894 from 26 others

What the payments were for

  • Food & beverage$2,430100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,438 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$23,885
Medicare patients
178
Services billed
547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$19,110
TrulicityDulaglutide12$15,368
MounjaroTirzepatide12$12,659
XareltoRivaroxaban12$8,231
Breo ElliptaFluticasone/Vilanterol12$4,845
Atorvastatin Calcium103$636
Nano 2nd Gen Pen NeedlePen Needle, Diabetic11$596
Albuterol Sulfate HfaAlbuterol Sulfate25$577
Gabapentin29$428
Pantoprazole Sodium45$428
Levothyroxine Sodium41$328
Metoprolol Succinate20$247
Omeprazole26$247
Amlodipine Besylate51$225
Methylprednisolone32$217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$345$28,02724 claims
PfizerEliquis$67$19,11015 claims
Johnson & JohnsonXarelto$76$8,23112 claims
GSKBreo Ellipta$20$4,84512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.

Other family in Buford

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →